Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or ...

Proteinuria is a condition characterised by the presence of excess protein, mainly albumin, in the urine. Generally, the kidneys filter waste products and excess fluids from the blood and excrete them ...

New drugs, dietary changes can help reduce proteinuria ...

The U.S. Food and Drug Administration on Tuesday granted accelerated approval to Vera Therapeutics Inc.’s VERA Trutakna ...

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...

Proteinuria is an unusually high amount of protein in your pee (urine). The condition is often a sign of kidney disease. Your kidneys are filters that don't usually let a lot of protein pass through.

Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL ...

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), ...

Proteinuria affects most people with complement 3 glomerulopathy (C3G). Protein in urine is one of the strongest indicators of disease progression. Reducing proteinuria can slow the progression of C3G ...

It has not been established whether atacicept slows kidney function decline long-term, how ...

Proteinuria refers to elevated protein levels in the urine. It is not a disease but a sign that the kidneys are not correctly filtering blood, possibly due to a kidney condition. Several proteins may ...